Design of ligands that provide receptor selectivity has emerged as a new paradigm for drug discovery of G protein-coupled receptors, and may, for certain families of receptors, only be achieved via identification of chemically diverse allosteric modulators. Here, the extracellular vestibule of the M 2 muscarinic acetylcholine receptor (mAChR) is targeted for structure-based design of allosteric modulators. Accelerated molecular dynamics (aMD) simulations were performed to construct structural ensembles that account for the receptor flexibility. Compounds obtained from the National Cancer Institute (NCI) were docked to the receptor ensembles. Retrospective docking of known ligands showed that combining aMD simulations with Glide induced fit docking (IFD) provided much-improved enrichment factors, compared with the Glide virtual screening workflow. Glide IFD was thus applied in receptor ensemble docking, and 38 top-ranked NCI compounds were selected for experimental testing. In [ 3 H]Nmethylscopolamine radioligand dissociation assays, approximately half of the 38 lead compounds altered the radioligand dissociation rate, a hallmark of allosteric behavior. In further competition binding experiments, we identified 12 compounds with affinity of ≤30 μM. With final functional experiments on six selected compounds, we confirmed four of them as new negative allosteric modulators (NAMs) and one as positive allosteric modulator of agonist-mediated response at the M 2 mAChR. Two of the NAMs showed subtype selectivity without significant effect at the M 1 and M 3 mAChRs. This study demonstrates an unprecedented successful structure-based approach to identify chemically diverse and selective GPCR allosteric modulators with outstanding potential for further structure-activity relationship studies.
H]Nmethylscopolamine radioligand dissociation assays, approximately half of the 38 lead compounds altered the radioligand dissociation rate, a hallmark of allosteric behavior. In further competition binding experiments, we identified 12 compounds with affinity of ≤30 μM. With final functional experiments on six selected compounds, we confirmed four of them as new negative allosteric modulators (NAMs) and one as positive allosteric modulator of agonist-mediated response at the M 2 mAChR. Two of the NAMs showed subtype selectivity without significant effect at the M 1 and M 3 mAChRs. This study demonstrates an unprecedented successful structure-based approach to identify chemically diverse and selective GPCR allosteric modulators with outstanding potential for further structure-activity relationship studies.
GPCR | allosteric modulators | ensemble docking | affinity | cooperativity T he largest group of signal-transmitting proteins at the cell surface is the superfamily of G protein-coupled receptors (GPCRs) (1) that account for targets of ∼40% of currently marketed drugs. For decades, the development of ligands in traditional GPCR-based drug discovery has focused on targeting the primary endogenous ligand (orthosteric) binding site of the receptor (2) , guiding the development of most classical orthosteric agonists, inverse agonists, and antagonists (3) (4) (5) (6) . However, modern discovery targeting GPCRs is characterized by an alarmingly high attrition rate (7) . Such moderate clinical outcome can partly be attributed to the inability of most ligands to selectively target one receptor among a family of GPCR subtypes. Many receptor subtypes of GPCR families often exhibit a highly conserved orthosteric binding pocket, such that a single ligand can interact with several receptors simultaneously, leading to the activation/inactivation of multiple receptors, sometimes with opposing of their signaling profiles, contributing to off-target side effects (8) . One representative case of a GPCR family displaying dramatically low subtype selectivity is the muscarinic acetylcholine receptors (mAChRs), composed of five distinct subtypes, M 1 -M 5 mAChRs, that each binds the endogenous ligand, ACh, with similar affinity. These receptors are broadly distributed within both the central and peripheral nervous systems, as well as various peripheral organs (9) .
However, GPCRs often exhibit multiple binding cavities in their structures (10, 11) . It is thus possible to design and synthesize ligands capable of binding receptors, away from their orthosteric sites, in less conserved allosteric pockets (12) . These ligands, called allosteric modulators, can bind to a GPCR concomitantly to the endogenous (orthosteric) ligand, altering its binding affinity and/or cellular-signaling efficacy, ultimately resulting in a modified pharmacological profile of the ligand-receptor complex (3, 13) . Combining their modulatory effects with their potential for selective interaction with less conserved binding sites, allosteric modulators represent an alternate therapeutic approach to treat GPCR-related diseases (14, 15) . Unfortunately, despite major interest in targeting allosteric sites of GPCRs, the discovery of allosteric modulators of GPCRs has mainly been serendipitous, with a surprising paucity of structure-based approaches. With recent advances in structural biology techniques, a growing number of GPCR structures have been solved, including four members of the mAChR family (16) (17) (18) (19) , In particular, the M 2 mAChR has been crystallized in both an inactive state bound by the 3-quinuclidinyl-benzilate (QNB) antagonist (16) and an active state bound to the high-affinity
Significance
Chemical diversity has recently risen as key structural feature for the discovery of novel selective drugs of G protein-coupled receptors (GPCRs). However, the traditional drug discovery technique of combinatorial chemistry coupled to high-throughput screening has become less attractive because of its immense financial impact. To address this problem, we implemented a computer-aided drug design approach, using the M 2 muscarinic acetylcholine receptor (mAChR) as a GPCR model, and performed computational enhanced sampling simulations to account for the receptor flexibility. Through iterative molecular docking and experimental testing, half of the 38 computationally selected National Cancer Institute compounds were validated as allosteric modulators of the M 2 mAChR. Our method successfully identified positive and negative allosteric modulators of M 2 mAChR with unprecedented chemical diversity.
agonist, iperoxo (IXO), and a G-protein mimetic nanobody (18) . Furthermore, the M 2 mAChR is also the first and only GPCR that has been cocrystallized with a positive allosteric modulator (PAM), LY-2119620, bound in the extracellular vestibule (18) . Although these crystal structures provided enormously important insights into different specific conformational states, as well as atomistic protein-ligand interactions of GPCRs, they nonetheless represent snapshots of the highly dynamic nature of GPCRs (20) . To address the above issue, extensive computational simulations have been performed to characterize the structural dynamics of GPCRs (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . All-atom molecular dynamics (MD) simulations are capable of exploring large-scale conformational changes during both receptor activation (23) and deactivation (20) by using fast supercomputers. Moreover, long-timescale MD simulations captured ligand binding to GPCRs (29) , in particular for several prototypical negative allosteric modulators (NAMs) of the M 2 mAChR (30) . In recent studies, we have also successfully depicted the activation of both the M 2 and M 3 mAChRs in accelerated MD (aMD) simulations (31) (32) (33) .
In the present study, we combined computational aMD simulations and virtual screening with experimental binding and functional assays to identify and validate allosteric modulators of the M 2 mAChR. The discovery of allosteric modulators with chemically novel structures will undoubtedly increase the potential for better receptor subtype selectivity. Based on the hypothesis that incorporation of receptor flexibility is key to effective GPCR drug design (34, 35) , we used aMD simulations to construct structural ensembles for molecular docking in the extracellular vestibule of the receptor. Ensemble docking of chemical compounds obtained from the National Cancer Institute (NCI) compound library (36) was performed to identify new potential allosteric modulators. The computationally selected lead compounds were then tested experimentally to investigate their binding and functional properties. We report here a successful structure-based design approach and several chemically diverse allosteric modulators of the M 2 mAChR. An overview of the procedure followed is shown in Fig. 1 .
Results

Docking Based on aMD Simulations and Glide Virtual Screening
Workflow. By using X-ray structures of the inactive QNB-bound and active IXO-nanobody-bound M 2 mAChR, aMD simulations were carried out to construct structural ensembles to account for receptor flexibility (SI Appendix, Table S1 ). Meanwhile, a compound library was prepared from the NCI Diversity Set (∼1,600 compounds) by using LigPrep in the Schrödinger package. Docking of known orthosteric ligands against the receptor X-ray structures and aMD structural ensembles was first carried out by using Glide virtual screening workflow (VSW) (Schrödinger, LLC). Overall, retrospective docking of the antagonists and agonists using aMD structural ensembles provided significantly higher enrichment factors than using the X-ray structures alone (SI Appendix, Tables S3 and S4). Particularly, dihedral aMD ensembles of the active IXO-nanobody-bound receptor led to improved docking, compared with dual-boost aMD ensembles for the inactive QNB-bound receptor. This result is largely because of greater flexibility of the active GPCR state compared with the inactive state (37) , and higher acceleration is thus needed for conformational sampling of the latter. In the first round, ensemble docking of the NCI compounds against aMD simulation ensembles of the extracellular allosteric site in the inactive M 2 mAChR was performed to identify potential allosteric modulators. Ten top-ranked compounds were selected for experimental testing using radioligand binding assays. Results showed that one of these compounds, NSC-46385, significantly slowed the dissociation rate of the Fig. S3 ), but with low binding affinity for the M 2 mAChR (≥100 μM) (SI Appendix, Table S2 ). This poor performance was likely because of the fact that the orthosteric site is deeply buried in the receptor, whereas the extracellular allosteric site is exposed on the receptor surface, involving flexible residues such as Trp-422 7.35 (18, 38) .
Docking Based on aMD Simulations and Glide Induced Fit Docking.
In an effort to optimize our docking protocol and increase the compound success rate, we performed extensive retrospective docking in the second round, using a Glide induced fit docking (IFD) method that scans for different conformations of residue side chains of the protein. Moreover, because IFD calculations are very computationally expensive (∼200 CPU hours for every 100 compounds per receptor structure), high-throughput virtual screening (HTVS) was first applied to select the top 100 compounds, which were then subjected to IFD to improve their ranking. Overall, docking of aMD receptor ensembles using the Glide HTVS+IFD provided much improved enrichment factors compared with using the Glide VSW. For the active IXOnanobody-bound receptor, the Glide HTVS+IFD on aMD structural ensembles provided the greatest enrichment factors when the average binding energy (BE avg ) was used for ranking (SI Appendix, Table S5 ). Dihedral aMD simulation was able to sufficiently sample flexible regions on the receptor surface, and in combination with Glide IFD, can fully account for the receptor flexibility for docking. Ensemble docking combining aMD simulation and Glide HTVS+IFD (with BE avg for ranking) was thus applied to identify allosteric modulators targeting the active IXO-nanobody-bound M 2 receptor. Surprisingly, for the inactive QNB-bound receptor, the Glide HTVS+IFD on the X-ray structure provided the highest enrichment, followed by Glide HTVS+ IFD on the dihedral aMD structural ensemble when the minimum binding energy (BE min ) was used for ranking (SI Appendix, Table S6 ). Based on this finding, the X-ray and dihedral aMD simulation structures were combined to form the final structural ensemble, and ensemble docking using Glide HTVS+IFD (with BE min for ranking) was adopted for the following virtual screening of the inactive QNB-bound M 2 mAChR.
Compounds Selected Through Optimized Ensemble Docking. A list of 50 top-ranked compounds was obtained from virtual screening of the NCI Diversity Set targeting the active IXO-nanobody-bound M 2 mAChR (SI Appendix, Table S7 ) and another 50 compounds targeting the inactive QNB-bound receptor (SI Appendix, Table  S8 ). Among the computationally predicted lead compounds, seven were shared between the two lists (SI Appendix, Table S9 ). Because these seven compounds could have higher probability of binding the M 2 mAChR in both the inactive and active states ("cross hits"), they were selected first for experimental testing. Next, for the active M 2 mAChR, 2 lead compounds that seemed to contain scaffolds of known ligands were selected, along with another 14 compounds that were ranked among the top 20 of the predicted highest-affinity binders. For the inactive M 2 receptor, 3 lead compounds with certain scaffolds of known ligands and 12 compounds that were ranked among the top 20 of the predicted highest-affinity binders were added to the list. Compounds with known scaffolds were used to rationalize our findings, whereas those with chemically diverse and yet-unknown scaffolds could potentially be novel allosteric modulators. In summary, a set of 38 total compounds was collected and ordered from NCI for experimental testing (SI Appendix, Table S9 ). Table 1 lists the top-ranked compounds binding the active and/or inactive M 2 mAChR, for which experimental binding affinities were also determined (more detailed discussion is provided below). For compounds that bind the active receptor, the root-mean-square error (rmse) between experimental and computationally predicted affinities is 2.1 kcal/mol when BE avg obtained from ensemble docking is used for the latter or 4.2 kcal/mol by using BE min . The rmse values for compounds binding to the inactive receptor are 5.0 and 4.7 kcal/mol by using BE avg and BE min , respectively. Notably, significantly higher binding affinities could be obtained by using aMD simulation structures (BE min from ensemble docking) than using the crystal structures. This finding suggests that the receptor conformational change captured through aMD simulation is able to facilitate ligand binding. When only the crystal structures were used for virtual screening, ∼50-60% of the experimentally confirmed NCI ligands of the M 2 mAChR could have been missed in this study (Table 1) . Fig. S4 ). In the absence of any modulator, at a saturating concentration of atropine to prevent the reassociation of [ 3 H]NMS, the radioligand dissociation rate was estimated at k off = 0.079 ± 0.01 min −1 (n = 2; mean ± SD). Comparably, in the presence of a concentration of 100 μM of three structurally distinct well-known allosteric modulators, the PAM of Units for the binding energies (BE) are kcal/mol. The experimental binding energies were converted from pK B as BE = RT ln K B , where R is the gas constant, T is the experimental temperature (310 K), and K B is the binding equilibrium constant. Based on retrospective docking, compounds binding to the active receptor (R*) are ranked according to the ensemble-averaged binding energy (BE avg ), and those binding to the inactive receptor (R) are ranked according to the minimum binding energy obtained from ensemble docking (BE min ). n.a., not applicable.
Logα NMS , defining the type of allosteric effect against the radioligand (SI Appendix, Fig. S4 C and D) . For the 19 selected NCI compounds that slowed the dissociation rate of [ Table S10 ). Fig. 2 B and C displays the pK B and Logα NMS estimates for the 12 NCI compounds that slowed the dissociation rate of [ Fig. 3 . To quantify the allosteric effect of these NCI compounds on agonist affinity, we performed three-way interaction studies between [ 3 H]NMS and IXO and defined the cooperativity between each of the 12 NCI compounds and the agonist (Fig. 2D and SI Appendix, Table S10 ). For the NCI compounds that exhibited high degrees of cooperativity with the radioligand, we performed full interaction curves (i.e., concentration inhibition curve of IXO in the presence of increasing concentrations of modulator). For the two NCI compounds that had no effect on the specific binding of [ 3 H]NMS alone, we performed titration interaction curves (i.e., single fixed concentration of IXO with increasing concentrations of modulators). This latter method is efficient for modulators with limited cooperativity with the orthosteric probe and has the advantage of saving considerable amounts of compounds and time (see SI Appendix for more details). Of the 12 NCI compounds investigated, 7 were NAMs of IXO binding with high to medium negative cooperativity (−3 ≤ Logα IXO ≤ −0.70), 2 were NALs and did not affect the affinity of IXO (NSC-305798 and -122253), and 3 appeared to enhance the binding of IXO for the M 2 mAChR (NSC-322661, -13316, and -654260) (Fig. 2D) . Fig. 3 and their specific allosteric properties at the M 2 mAChR, we finally selected 5 compounds (NSC-322661, -121868, -13316, -147866, and -99657), as well as a ligand that appeared to have no effect on binding experiments as a negative control (NSC-93427) to carry on validation of their functional signaling effects (Fig. 4) . The effect of each of these six NCI compounds was investigated on the functional response of IXO. The functional assay chosen for this study was phosphorylation of extracellular signal-regulated kinases 1/2 (pERK1/2) because it is downstream of multiple receptor activation pathways and therefore an ideal functional output for detection of small changes in receptor function. We first performed timecourse experiments to determine the stimulation period of the selected NCI compounds, alongside IXO. As expected, IXO showed a robust stimulation of pERK1/2 that peaked at 5 min (SI Appendix, Fig. S6A ). Among the NCI compounds, none appeared to induce the stimulation of pERK1/2 at any time points measured, apart from NSC-322661, which displayed a weak response at ∼7 min. The incubation times of 5 min for IXO and 7 min for NCI compounds were then chosen as the stimulation periods for subsequent functional experiments. To provide estimates of functional cooperativity with IXO (Logαβ IXO ), we used the titration format, whereby increasing concentrations of each selected NCI compound were applied to an EC 70 concentration of IXO, in parallel to a full-concentration response analysis of the agonist alone (Fig. 4  A-F) . Using an allosteric operational model to fit the data, we were able to estimate the compounds' binding affinity (pK B ), as well as functional cooperativity with the agonist, Logαβ IXO . Four NCI compounds, NSC-147866, -121868, -99657, and -13316, significantly reduced the ability of 0.03 nM IXO to induce pERK1/2 (Logαβ IXO ∼ −3), indicating strong negative modulation on the agonist-mediated response (Fig. 4 B-D) . Affinities of the four modulators were estimated from our functional assays as pK B = 5.49 ± 0.34 (NSC-147866), 5.85 ± 0.15 (NSC-121868), 5.46 ± 0.16 (NSC-99657), and 5.21 ± 0.23 (NSC-13316), all strongly agreeing with their respective radioligand equilibrium binding measurements. In contrast, one compound, NSC-322661, showed a small, but consistent, increase of pERK1/2 levels in the presence of 0.03 nM IXO (Logαβ IXO = 0.74 ± 0.22), suggesting that this compound was a PAM of agonist-mediated response (Fig. 4A) . As anticipated, NCS-93427 did not show any effect on IXO-mediated pERK1/2 response. Finally, we selected two NCI compounds (NSC-322661 and -13316) to perform full interaction studies between the modulators and IXO (Fig. 4 G and H) . Using an operation model of allosterism constraining the affinity of each modulator (as defined by radioligand binding against [ 3 H]NMS), we defined the functional cooperativity of the two compounds for IXO, Logαβ IXO equal to approximately −3 for NSC-13316 and Logαβ IXO = 0.36 ± 0.17 for NSC-322661. For the latter compound, the cooperativity with the agonist was slightly lower than that estimated from the titration method, most likely because of the additional weak partial agonist effect of the compound alone that would affect the basal levels of pERK1/2 at the single concentration of agonist used. Together, these results suggest that our ensemble docking method combining aMD simulations with Glide HTVS+IFD was successfully applied to identify both PAMs and NAMs of the M 2 mAChR. The most favorable binding poses predicted from ensemble docking calculations revealed that NSC-322661 (a PAM of agonist function) is predicted to cause only very small conformational changes in the active IXO-nanobodybound conformation of the receptor (Fig. 5A) . In comparison, NSC-13316 (a NAM of agonist function) binds much deeper into the receptor and is predicted to induce larger structural rearrangements of the TM helices (Fig. 5B) . The largest conformational changes occurred in residues Y426 7.39 , W422 7.35 , Y83 2.64 , and F181 in the extracellular loop (ECL) 2. Therefore, NSC-13316 tends to disrupt the receptor active conformation, which leads to negative allosteric modulation of the M 2 mAChR.
Subtype Selectivity of Modulators on Agonist-Mediated Responses.
To assess the potential subtype selectivity of the NCI compounds, we finally investigated their effect on IXO-mediated pERK1/2 responses at the two most peripherally expressed subtypes, M 1 and M 3 mAChRs. With the same method as used for the M 2 mAChR, we determined the levels of pERK1/2 upon IXO addition in the presence of absence of each of the six NCI compounds tested previously at the M 3 ( Fig. 6 ) and M 1 mAChRs (Fig. 7) . The three cross-hit compounds, NSC-322661, -121868, and -13316, appeared to antagonize the agonist-mediated response of IXO for both receptors. Excitingly, the two NCI compounds that were selected based on either the receptor active state (NSC-147866) or the inactive state (NSC-99657) had no significant effect on IXO-mediated pERK1/2 levels at either the M 3 or the M 1 mAChR (Figs. 6 C and D and 7 C and D). After a one-way ANOVA statistical test, comparing the maximal responses of IXO in absence and presence of a 10 μM concentration of each NCI compound, these two NCI compounds showed negligible differences, similar to the negative control NSC-93427 that had no effect on the M 2 mAChR. According to ensemble docking calculations, NSC-147866 and -99657 prefer to bind the cleft formed between ECL2 and ECL3, which is significantly different from the three cross-hit compounds that are predicted to bind to approximately the center of the extracellular vestibule ( Fig. 5 C and D) . Notably, NSC-147866 interacts with Phe-181 in ECL2, and NSC-99657 forms interactions with Asn-410 6 .58 and Ile-417 in ECL3. These residues exhibit great diversity across five subtypes of the mAChRs (19) , and comparison of the X-ray structures of the M 2 and M 3 receptors showed significant differences in the ECL2-ECL3 cleft (17) , which apparently contribute to binding selectivity of the NSC-147866 and -99657 compounds.
Discussion mAChRs are involved in some of the most debilitating diseases, both centrally-such as Parkinson's disease, Alzheimer's disease, and schizophrenia-and peripherally, such as asthma and heart dysfunctions (40) . Although, several orthosteric cholinergic drugs have made their way to the market, all of them exhibit side effects. For example, trihexyphenidyl, a muscarinic antagonist used in some cases for the treatment of Parkinson's disease, induces drowsiness, anxiety, and blurred vision, as well as tachycardia (41, 42) . Such high levels of off-target effects are primarily due to the poor selectivity profile of trihexyphenidyl, antagonizing multiple mAChR subtypes simultaneously. This lack of selectivity from orthosteric site-targeting drugs is the consequence of a high degree of conservation of sequences and structures between each member of the mAChR family. It is thus not surprising that GPCR-based drug discovery, particularly for the mAChR family, has been recently shifting focus toward possibly less conserved and potentially more selective regions of the receptors, such as allosteric sites. Like most GPCRs, allosteric sites have been identified for the mAChRs; for these receptors, these sites are located predominantly within the extracellular loops and the top of the transmembrane domains. To date, the majority of allosteric ligands that have been identified for the mAChRs have come out of high-throughput screening programs and are lacking chemical diversity in their scaffolds. To address this issue, we have developed a computational-based method to efficiently identify novel allosteric scaffolds for the M 2 mAChR, with high potential for future development of more selective and more potent allosteric modulators. For instance, the M 2 mAChR plays a major role in modulating cardiac functions, whereby activation of this receptor typically results in a decrease in the heart rate and a reduction in the heart contraction forces. Therefore, selective drugs that could either enhance or inhibit the M 2 mAChR may be beneficial for treating heart diseases involving abnormal heart rate and heart failure (43) . Through iterative computational modeling and experimental testing, here we report a successful structure-based approach for discovering chemically diverse allosteric modulators of the M 2 mAChR. We have combined aMD enhanced sampling simulations with Glide IFD to fully account for flexibility of the receptor in both the backbone and side chains. Experimental assays, including radioligand kinetic dissociation, equilibrium competition binding experiments, and functional assays, were used to test the computationally selected lead compounds and highlight their distinct allosteric properties as either PAMs or NAMs, depending on the orthosteric ligand used as probe.
Computationally, the Glide IFD method provided much improved docking compared with the Glide VSW. By using Glide IFD combined with aMD simulations for ensemble docking, 12 of the 38 computationally selected compounds were confirmed as allosteric ligands of the M 2 mAChR, with ∼3−30 μM (∼5.6−8.5 kcal/mol) binding affinity (Table 1 and Fig. 2B ), confirming the critical importance of incorporating receptor flexibility into GPCR drug design. For instance, by using only the X-ray crystal structures for virtual screening, it appears that ∼50−60% of the experimentally confirmed NCI ligands of the M 2 mAChR would have been missed. Furthermore, the rmse values between docking and experimental binding energies were ∼4−5 kcal/mol, although these differences were significantly reduced, to 2.1 kcal/mol where BE avg was used for docking against the active M 2 receptor. Experimentally, we successfully validated 19 NCI compounds as allosteric modulators of the M 2 mAChR, with 12 with affinity ≤30 μM. Additionally, of the 19 NCI compounds that did not significantly alter the dissociation rate of [ mAChR, as opposed to potential competitive ligands. Further validating our method, the NCI compounds that share structural similarities with already known modulators (e.g., the strychninelike NSC-121868) did come back as allosteric ligands in our experimental testing. Specifically, when investigating the effect of strychnine on the M 2 mAChR, we confirmed that the modulator was able to bind to the allosteric site with an affinity close to micromolar, pK B = 5.78 ± 0.04, and exhibit positive cooperativity with the radioligand [ 3 H]NMS, Logα NMS = 0.21 ± 0.06 Fig. S4C ), confirming previous findings (44) . Similarly, the binding affinity of NSC-121868 was very close to that of strychnine (SI Appendix, Fig. S4D ). In contrast, we identified negative cooperativity between NSC-121868 and [
3 H]NMS, suggesting that the small structural changes between strychnine and NSC-121868 (i.e., stereospecificity of a central carbon in the core and addition of a phenylethene group) had no effect on the binding affinity, but rather appeared to switch the ligand from PAM to NAM for antagonist binding. Among the seven computationally selected lead compounds that were predicted to bind both the active and inactive M 2 mAChR conformations, five of them indeed exhibited binding cooperativity with the antagonist [ 3 H]NMS (Fig. 2C) and/or the agonist IXO (Fig. 2D) , whereas the remaining two (NSC-106464 and -177862) were not effective in slowing dissociation of the antagonist radioligand and are thus most likely nonbinders. From the 16 compounds that were predicted to predominantly bind the active conformation of M 2 mAChR, 3 of them (NSC-308814, -379697, and -147866) exhibited affinity at ∼10μM. Four of 15 compounds that were predicted to specifically bind the inactive conformation of the receptor were also confirmed as ∼30 μM binders. Thus, we can confirm that using our ensemble docking method, selecting compounds that were computationally binders of both active and inactive conformations of the receptor, we achieved an outstanding 70% success rate in identifying allosteric ligands. In comparison, by using either the active state or the inactive state X-ray conformations, the success rate of identifying allosteric modulators was reduced to ∼20−25%.
Importantly, substantial chemical diversity was found among the NCI compounds that bind allosterically to the M 2 mAChR (Fig. 3) . Within the subset of five ligands selected based on both active and inactive receptor conformations, only NSC-322661 and -13316 showed some chemical identity, both quinolonebased ligands, which is a scaffold that has been shown to bind and antagonize the muscarinic receptors, such as NSC-23766 (45) . Additionally, NSC-143491 is an anthraquinone-based ligand. Anthracycline ligands have been shown to be highly effective anticancer drugs, although they are also well known for their deleterious cardiotoxicity side effects (46) . Indeed, mitoxantrone was shown to bind to muscarinic receptors in isolated heart muscles of guinea pigs, and potentially in an allosteric manner, because the inhibition binding curve of mitoxantrone appeared incomplete against the antagonist radioligand, [ 3 H]QNB (47) . Another anthraquinone, doxorubicin, has been shown to reduce the maximal negative ionotropic effects of carbachol in isolated guinea pig hearts (48), consistent with an antagonist effect on the muscarinic system in this rodent. In summary, most of the NCI compounds that we identified as allosteric modulators are small organic molecules, containing several heteroatoms. They could easily be chemically modified, and therefore have great potential to pave the way for lead optimization to design more potent allosteric modulators of the M 2 mAChR. Excitingly, of the selected five NCI compounds that interacted allosterically at the M 2 mAChR with IXO, two of them (NSC-147866 and -99657) showed no effect on the agonist-mediated pERK1/2 responses at the M 3 subtype. Ensemble docking calculations showed that, unlike the three cross-hit compounds, which bind similarly to the center of the extracellular vestibule in both the active and inactive states of the M 2 mAChR, NSC-147866 and -99657 prefer to bind the cleft formed between ECL2 and ECL3. The ECL2-ECL3 cleft showed significant differences in the M 2 and M 3 X-ray structures (17) and involved diverse residues across different subtypes of the mAChRs (19) . These differences likely contribute to binding selectivity of the two selected NCI compounds.
Conclusions
In this study, we examined the applicability of aMD enhanced sampling simulations and receptor ensemble docking in characterization of the receptor flexibility and successful design of GPCR allosteric modulators. Using the rather small NCI chemical database (∼1,600 compounds), we developed a successful method of identification of chemically diverse allosteric modulators of the M 2 mAChR. These ligands are mostly small organic molecules and show potential for structure-activity relationship studies to develop more potent allosteric modulators. This work will set the stage for future lead optimization efforts that combine computational free energy calculations and synthetic biochemical experiments. It will be important to examine the selectivity of these chemically diverse allosteric modulators on the M 2 receptor vs. other subtypes of mAChRs. This work can also provide useful guidance for future drug design efforts using larger chemical databases [e.g., ZINC (49) and ChemBridge (50)], targeting allosteric sites of the M 2 receptor and other medically important GPCRs.
Methods aMD simulations were carried out on both the inactive QNB(antagonist)-bound and active IXO(agonist)-nanobody-bound M 2 mAChR (SI Appendix, Fig. S1 ). Structural clustering of the simulation snapshots was carried out to construct representative receptor ensembles that account for the receptor flexibility. In the first round, 10 top-ranked compounds were selected from Glide VSW calculations for experimental testing. Although one of these compounds significantly slowed down dissociation of the antagonist radioligand, [ 3 H]NMS, which is a hallmark of the allosteric mode of action, none of them exhibited high affinity in the binding assays. In the second round, retrospective docking of known ligands, including antagonists, agonists, and allosteric modulators, showed that Glide HTVS+IFD provided much improved docking enrichment factors compared with the VSW. It was thus applied for prospective docking of chemical compounds obtained from the NCI chemical database to select 38 new top-ranked compounds for experimental testing. From this second set, 19 NCI compounds that significantly slowed the dissociation rate of the antagonist radioligand were selected for further radioligand binding experiments, including a direct two-way equilibrium competition binding with [ 
